intestin
viral
pathogen
enorm
social
econom
impact
worldwid
gastrointestin
virus
excret
fece
transmit
orofec
rout
direct
contact
infect
individu
contact
consumpt
water
contamin
food
intestin
viral
infect
cours
diarrhea
commonli
treat
oral
parenter
rehydr
therapi
although
altern
treatment
base
probiot
gain
interest
treatment
prevent
infecti
diarrhea
probiot
live
bacteria
gener
belong
lactic
acid
bacteria
group
bifidobacteria
also
includ
bacilli
yeast
gener
microorgan
common
member
intestin
microbiota
also
employ
manufactur
mani
ferment
food
numer
report
identifi
sever
bacteri
probiot
strain
use
tool
treatment
intestin
disord
mani
clinic
studi
indic
specif
probiot
strain
lactobacillu
rhamnosu
gg
lgg
bifidobacterium
posit
impact
gastroenter
sever
anim
clinic
trial
strain
document
reduc
sever
durat
diarrhea
oral
intak
posit
effect
believ
base
immunoregul
give
way
enhanc
cellular
immun
respons
higher
level
virusspecif
immunoglobulin
howev
mechan
exist
explain
antagonist
effect
probiot
viral
infect
includ
direct
interact
virus
bacteria
block
specif
viral
receptor
target
cell
evid
obtain
virus
replic
gastrointestin
tract
recent
gastrointestin
virus
demonstr
virus
take
advantag
microbiotatrigg
process
microbiotaderiv
substanc
replic
howev
case
viral
infect
inhibit
mechan
depend
presenc
intestin
microbiota
achiev
direct
indirect
effect
gener
relat
immunoregul
pfeiffer
sonnenburg
wilk
et
al
dual
role
microbiota
exploit
togeth
use
probiot
develop
new
therapeut
strategi
fight
viral
infect
great
varieti
virus
target
gastrointestin
tract
although
caus
gastroenter
import
enter
virus
correspond
rotavirus
rv
reovirida
famili
norovirus
nov
calicivirida
famili
enter
adenovirus
adenovirida
famili
astrovirus
astrovirida
famili
enterovirus
picornavirida
famili
buesa
rodriguez
diaz
nov
rv
far
relev
viral
group
respons
gastroenter
due
relev
exist
clinic
trial
probiot
focu
chapter
howev
locat
enter
adenovirus
defin
subtyp
second
agent
respons
infantil
gastroenter
astrovirus
may
respons
viral
diarrhea
incid
develop
develop
countri
one
member
kubovirus
enterovirus
respons
gastroenter
outbreak
due
consumpt
contamin
food
aichi
viru
final
import
repres
enterovirus
polioviru
replic
intestin
primarili
asymptomat
although
final
target
nervou
system
result
poliomyel
except
polioviru
data
interact
human
gastrointestin
virus
differ
rv
nov
microbiota
socal
pparticl
known
ctermin
portion
protein
amino
acid
protrud
domain
p
domain
abl
form
dimer
autoassembl
subvir
particl
icosahedr
symmetri
call
pparticl
nm
diamet
consist
pdomain
dimer
norovir
pparticl
retain
capac
bind
receptor
specif
nov
genotyp
abl
induc
product
block
antibodi
make
togeth
easi
product
prokaryot
host
like
escherichia
coli
use
tool
studi
bind
specif
vaccin
develop
tan
et
al
third
model
nov
constitut
murin
nov
mnov
genogroup
gv
felin
caliciviru
mnov
abl
vitro
infect
b
cell
macrophag
produc
asymptomat
infect
mice
concomit
viral
shed
fece
kind
nov
surrog
constitut
almost
exclus
altern
except
infect
volunt
studi
inactiv
nov
differ
food
treatment
howev
suscept
mnov
differ
temperatur
environment
food
process
condit
total
differ
human
nov
question
util
approach
richard
cellular
attach
nov
recogn
glycoconjug
present
cell
surfac
part
abh
system
human
histoblood
group
antigen
hbga
lewi
antigen
b
x
present
saliva
gastroduoden
mucosa
erythrocyt
differ
abh
system
among
individu
impact
suscept
infect
nov
genotyp
display
differ
bind
profil
huang
et
al
addit
secretor
statu
also
import
individu
mutat
gene
encod
fucosyltransferas
involv
hantigen
synthesi
secret
lack
abh
antigen
saliva
epitheli
cell
less
suscept
nov
infect
howev
nov
cellular
tropism
known
clear
whether
bind
hbga
cell
surfac
aid
cellular
attach
also
involv
subsequ
infect
process
gastrointestin
tract
constitut
one
complex
ecosystem
huge
bacteri
popul
locat
reach
bacteria
per
gram
content
speci
describ
part
ecolog
nich
despit
complex
phylogenet
divers
limit
bacteri
speci
present
belong
phyla
bacteroidet
firmicut
blottier
et
al
bacteri
composit
depend
individu
affect
mani
factor
genet
diet
health
statu
howev
core
microbiom
share
individu
probabl
reflect
import
physiolog
immun
function
attribut
microbiota
imbal
composit
refer
dysbiosi
link
seri
patholog
includ
inflammatori
bowel
diseas
obes
diabet
among
other
collado
et
al
de
moreno
de
leblanc
leblanc
intestin
immun
system
remain
hyporespons
endogen
microbiota
complex
cross
talk
establish
microbiota
epithelium
assur
time
prepar
immun
system
respond
microbi
pathogen
host
immun
system
abl
recogn
bacterialderiv
product
cell
wall
compon
peptidoglycan
lipopolysaccharid
lp
bacteri
dna
via
special
receptor
tolllik
receptor
tlr
trigger
seri
signal
event
end
matur
differenti
epitheli
immun
cell
mainten
intestin
barrier
gill
prasad
virus
infect
gastrointestin
mucosa
coevolv
gut
microbi
popul
surpris
occur
bacteri
pathogen
aspect
viru
infect
may
modul
presenc
microbiota
first
evid
link
microbiota
viral
suscept
deriv
use
two
model
limit
extens
employ
studi
germfre
antibiotictr
anim
usual
mice
first
model
advantag
complet
depriv
microbiota
therefor
role
intestin
bacteria
viral
infect
easili
studi
furthermor
effect
individu
bacteri
strain
probiot
commens
complex
defin
microbiota
studi
inocul
colon
germfre
anim
howev
anim
present
disadvantag
due
immatur
immun
system
alter
intestin
physiolog
second
model
treat
anim
antibiot
cocktail
simpl
econom
way
get
rid
microbiota
howev
approach
also
limit
sensit
antibiot
differ
bacteria
even
use
broadspectrum
antibiot
complet
deplet
microbiota
assur
earlier
evid
particip
intestin
microbiota
viral
suscept
obtain
anim
virus
virus
target
gastrointestin
tract
replic
dengu
viru
vector
mosquito
aed
aegypti
increas
gut
antibiotictr
insect
system
microbiota
shown
control
express
antimicrobi
peptid
regul
pathway
mediat
tlr
signal
xi
et
al
hypothes
mosquito
microbiota
enhanc
antivir
respons
basal
stimul
immun
system
second
exampl
role
microbiota
control
viral
replic
case
influenza
viru
germfre
antibiotictr
anim
infect
viru
show
exacerb
diseas
symptom
decreas
specif
igg
product
establish
microbiota
need
develop
adequ
antivir
respons
case
indirect
mechan
propos
microbiota
activ
inflammasom
induc
migrat
immun
cell
lung
lymph
node
prime
specif
tcell
respons
ichinoh
et
al
contrari
two
latter
case
microbiota
may
also
particip
process
result
enhanc
viral
infect
germfre
mice
less
suscept
develop
leukemia
induc
murin
leukemia
viru
isaak
et
al
postul
resist
infect
result
diminish
popul
target
immun
cell
viral
replic
germfre
mice
anoth
exampl
mous
mammari
tumor
viru
mmtv
transmit
offspr
milk
use
mechan
base
microbiota
evad
immun
system
mmtv
virion
abl
trigger
mean
bacteri
product
lp
result
product
immunosuppress
cytokin
block
antivir
respons
kane
et
al
case
mmtv
take
advantag
mechan
induc
toler
indigen
microbiota
evad
immun
respons
discuss
later
evid
particip
intestin
microbiota
deriv
compon
viru
infect
final
obtain
human
virus
infect
gastrointestin
tract
produc
gastroenter
poliovirus
nov
rv
case
posit
effect
microbiota
viral
infect
found
principl
seem
contradictori
protect
effect
diarrhea
usual
attribut
probiot
also
member
microbiota
evidenc
distinct
mechan
initi
intestin
bacteria
modul
infect
antagonist
effect
probiot
exhaust
studi
microbi
pathogen
clostridium
helicobact
salmonella
enteropathogen
e
coli
inhibitori
mechan
elucid
sever
case
lievinl
moal
servin
believ
mechan
also
appli
inhibit
viral
infect
probiot
interfer
viral
cycl
act
sever
step
interf
aspect
viral
replic
pathogenesi
protect
mucos
barrier
function
summar
figur
also
immunomodul
level
innat
adapt
respons
emerg
major
mechan
antivir
effect
mean
sever
mechan
still
poorli
understood
probiot
modul
specif
host
pathway
affect
synthesi
intestin
microbiota
promot
inhibit
viral
infect
sever
mechan
influenc
mucu
product
glycosyl
state
surfac
glycoprotein
case
target
viral
recognit
ii
competit
exclus
displac
attach
viral
receptor
iii
bacteria
promot
viru
retent
cell
surfac
structur
compon
deriv
need
viru
infect
mani
cytokin
eg
consequ
seri
modulatori
effect
immun
cell
increas
cytotox
phagocyt
capac
nk
cell
macrophag
immun
cell
b
lymphocyt
prolifer
differenti
last
effect
result
increas
antibodi
respons
gill
prasad
thu
adjuv
effect
probiot
document
vaccin
sever
viral
pathogen
hepat
b
polioviru
influenza
give
rise
increas
igg
iga
titer
similar
way
consumpt
ferment
milk
contain
lgg
demonstr
effect
promot
specif
iga
secret
cell
increas
plasma
iga
titer
rv
vaccin
rv
infect
kaila
et
al
effect
evidenc
differ
anim
model
studi
suggest
specif
probiot
abl
synthes
antivir
substanc
although
natur
still
unknown
botic
et
al
seo
et
al
mani
organ
acid
produc
ferment
carbohydr
lactobacilli
bifidobacteria
microbicid
activ
per
se
establish
use
vitro
model
acid
abl
inhibit
infect
virus
suggest
acid
environ
may
reduc
viral
infect
howev
fact
enter
virus
evolv
replic
gastrointestin
nich
therefor
adapt
thrive
environ
may
limit
effect
product
virucid
substanc
also
induc
host
cell
probiot
reactiv
oxygen
speci
product
h
nower
increas
lgg
lactobacillu
casei
shirota
strain
lactobacillu
pentosu
lactobacillu
plantarum
lactobacillu
fermentum
depend
combin
strain
cell
line
result
diminish
complet
abolish
disrupt
vitro
cultur
monolay
rv
infect
maragkoudaki
et
al
howev
experiment
model
argu
mode
action
infect
rv
cultur
cell
promot
chlorid
excret
link
increas
reactiv
oxygen
speci
mediat
viral
enterotoxin
effect
inhibit
supernat
probiot
yeast
saccharomyc
boulardii
prevent
rvinduc
oxid
stress
buccigrossi
et
al
probiot
yeast
proven
benefici
effect
rv
diarrhea
result
provid
new
clue
antirv
effect
probiot
antivir
molecul
whose
product
induc
respons
microbiota
defensin
peptid
strong
antibacteri
activ
describ
alphadefensin
bind
human
adenoviru
limit
viral
replic
vitro
prevent
viru
uncoat
cell
entri
process
howev
relev
phenomenon
vivo
establish
wilson
et
al
relationship
probiot
mucu
synthesi
proven
case
lgg
l
plantarum
abl
increas
mucin
secret
cultur
cell
upregul
express
gene
thick
mucu
layer
compar
width
epitheli
layer
repres
first
line
defens
infect
compos
mucin
glycoprotein
interact
microbiota
case
repres
first
anchor
site
sourc
nutrient
mani
enter
bacteria
time
dynam
renew
movement
link
transit
gastrointestin
tract
mean
constitut
besid
physic
barrier
limit
access
epitheli
cell
way
entrap
exclud
viral
particl
promot
elimin
fece
lactobacilli
bifidobacteria
also
possess
surfac
factor
promot
bind
intestin
mucu
compon
extracellular
matrix
protein
extracellular
factor
surfac
layer
protein
slpa
special
protein
mucos
bind
mucu
bind
pili
structur
found
lactobacilli
eg
lgg
bifidobacteria
occas
adhes
factor
consist
moonlight
protein
gener
cytoplasm
protein
target
surfac
still
unclear
export
mechan
chaperon
glycolyt
enzym
etc
case
mediat
interact
mucos
surfac
strain
l
plantarum
l
casei
lactobacillu
reuteri
lactobacillu
johnsonii
adhes
factor
possess
lectinlik
activ
help
colon
process
bacteria
may
particip
competit
exclus
displac
viru
target
cell
apart
probiot
strain
shown
directli
bind
virus
thu
lgg
bifidobacterium
lacti
two
strain
efficaci
viral
diarrhea
better
document
display
remark
bind
abil
rv
salminen
et
al
probiot
l
casei
e
coli
nissl
abl
bind
viral
particl
rubiodelcampo
et
al
natur
molecul
promot
bind
known
mani
viru
receptor
consist
glycosyl
protein
present
cell
surfac
thu
anticip
probiot
strain
express
surfac
glycosyl
protein
polymer
substanc
carbohydr
natur
mimick
viral
receptor
discuss
later
alreadi
report
enter
strain
possess
sugar
structur
surfac
resembl
hbga
abl
interact
nov
vlp
probiot
may
contribut
mainten
integr
intestin
epitheli
barrier
compromis
intestin
viral
infect
viral
diarrhea
compris
sever
mechan
result
increas
secret
water
electrolyt
paracellular
epitheli
permeabl
addit
epitheli
damag
apoptosi
occur
sever
probiot
strain
demonstr
capac
counteract
effect
via
distinct
mechan
therefor
mainten
intestin
homeostasi
probiot
may
help
keep
intestin
barrier
integr
lgg
secret
solubl
factor
cultur
medium
protein
member
machineri
cell
wall
biosynthesi
turnov
endolysin
protein
shown
act
akt
signal
pathway
activ
epiderm
growth
factor
receptor
result
protect
epithelium
vitro
vivo
apoptosi
trigger
inflammatori
cytokin
like
oxid
damag
chemic
induc
inflamm
also
lowmolecularweight
peptid
releas
lgg
induc
cytoprotect
heatshock
protein
result
apoptosi
resist
mainten
epitheli
structur
increas
express
protein
tight
junction
zonula
occludin
claudin
seth
et
al
lgg
also
increas
express
mice
vivo
lead
increas
mucu
product
thicken
intestin
mucu
layer
describ
may
protect
infect
character
proteic
factor
may
contribut
maintain
intestin
homeostasi
play
role
hostbacterium
cross
talk
cell
wallanchor
proteinas
l
casei
prtp
enzym
requir
milk
casein
degrad
proven
play
role
intestin
homeostasi
select
degrad
proinflammatori
cytokin
von
schilld
et
al
serpin
homologu
secret
bifidobacteri
speci
specif
inhibitor
proteas
human
neutrophil
elastas
suscept
reduc
tissu
damag
site
intestin
inflamm
ivanov
et
al
due
lack
simpl
model
studi
interact
rv
nov
intestin
microbiotaprobiot
studi
exist
matter
differ
strain
lactobacilli
shown
bind
surfac
pparticl
human
nov
genotyp
competit
experi
use
lactobacilli
pparticl
show
presenc
bacteria
inhibit
bind
subvir
particl
intestin
epitheli
cell
rubiodelcampo
et
al
observ
also
would
agreement
previou
report
show
specif
strain
lactobacillu
brevi
lactobacillu
gasseri
lactobacillu
salivariu
lactobacillu
acidophilu
isol
fece
display
surfac
lectinlik
activ
resid
slayer
protein
abl
bind
type
b
h
hbga
data
suggest
two
type
mechan
probiot
may
interfer
bind
nov
target
cell
first
probiot
may
inhibit
viral
bind
competit
exclus
block
viral
receptor
second
bind
virus
surfac
promot
elimin
fece
limit
viral
access
target
cell
intestin
isol
enterobact
sp
present
surfac
polymer
substanc
resembl
atyp
hbga
abl
bind
nov
vlp
genotyp
bind
capac
hbga
miura
et
al
presenc
close
serolog
relationship
b
h
hbga
present
gramneg
enterobacteria
belong
e
coli
salmonella
citrobact
proteu
klebsiella
pseudomona
serratia
explain
presenc
immunoglobulin
nonself
hbga
human
exist
hbga
activ
bacteria
gener
depend
express
differ
glycosyltransferas
encod
oantigen
synthesi
gene
cluster
respons
incorpor
polysaccharid
moieti
lp
gramneg
bacteria
recent
breakthrough
nov
research
repres
find
similar
murin
nov
human
nov
infect
lymphocyt
sinc
discoveri
human
nov
year
ago
multipl
attempt
reproduc
infect
vitro
cell
cultur
system
adequ
small
anim
model
fail
recent
demonstr
human
nov
infect
take
place
vitro
use
b
cell
host
infect
link
intestin
microbiota
stock
nov
isol
fece
filter
devoid
accompani
bacteria
much
less
infect
unfilt
nov
prepar
also
shown
enter
bacteria
enterobact
cloaca
express
htype
hbga
surfac
enhanc
nov
attach
infect
target
cell
dosedepend
manner
effect
observ
use
synthet
htype
hbga
howev
e
coli
strain
lack
hbga
activ
lp
show
effect
agreement
find
mnov
infect
antibiotictr
mice
reduc
compar
mice
normal
intestin
microbiota
microbiota
ablat
antibiot
also
prevent
persist
mnov
infect
mice
effect
depend
receptor
baldridg
et
al
suggest
intestin
microbiota
promot
mnov
persist
compon
innat
immun
system
counteract
although
addit
mechan
deriv
microbiota
exclud
interact
nov
intestin
bacteria
seem
crucial
factor
product
attach
viru
target
cell
biopsi
analysi
individu
infect
nov
infect
use
tissu
explant
point
intestin
epitheli
cell
target
human
nov
replic
evid
virus
may
present
differ
cellular
tropism
similarli
shown
vivo
infect
mnov
mice
target
b
lymphocyt
intestin
peyer
patch
whether
result
obtain
genotyp
could
extend
nov
genotyp
need
explor
case
new
find
open
door
kind
research
nov
biolog
elus
past
year
mechan
nov
use
hbga
molecul
deriv
microbiota
infect
known
earlier
studi
evidenc
vitro
bind
nov
vlp
sever
hbga
promot
uncharacter
stool
compon
particip
antibodi
protein
process
discard
effect
sensit
temperatur
harrington
et
al
rais
hypothesi
microbiota
lipid
polysaccharid
substanc
deriv
particip
process
similar
human
nov
mnov
demonstr
antibiot
treatment
mice
use
germfre
mice
reduc
rv
infect
uchiyama
et
al
persist
antirv
respons
term
specif
iga
secret
cell
link
reduc
sever
diarrhea
durat
also
found
anim
deplet
microbiota
therefor
two
viru
group
respons
major
gastroenter
reli
intestin
microbiota
infect
anoth
research
studi
particip
intestin
microbiota
infect
enter
virus
reveal
microbialderiv
product
also
import
viral
pathogenesi
human
poliovirus
infect
transgen
mice
express
polioviru
receptor
pvr
model
ablat
intestin
microbiota
antibiot
treatment
use
germfre
mice
result
reduc
viral
infect
demonstr
presenc
bacteri
strain
enhanc
viral
bind
pvr
infect
bacteri
compon
lp
respons
kuss
et
al
capsid
protein
polioviru
virion
bind
lp
bind
stabil
virion
make
heatstabl
bleachresist
robinson
et
al
specif
point
mutat
character
polioviru
present
reduc
interact
lp
render
less
infect
virus
therefor
two
differ
mechan
mediat
microbiota
involv
enhanc
polioviru
infect
virion
stabil
cell
attach
attach
requir
significantli
less
lp
stabil
robinson
et
al
polysaccharid
moieti
lp
need
detoxifi
lp
lipid
portion
remov
retain
stabil
abil
polioviru
polysaccharid
chitin
long
polym
nacetylglucosamin
glcnac
peptidoglycan
compon
bacteri
cell
wall
polym
carri
glcnac
similar
stabil
characterist
contrast
monomer
glcnac
chitohexaos
six
glcnac
residu
lack
effect
postul
polysaccharid
six
glcnac
residu
requir
robinson
et
al
relev
role
microbiota
viral
infect
view
doubleedg
sword
import
implic
use
probiot
vitro
experi
reveal
specif
probiot
strain
may
impact
bacteri
pathogen
adhes
thu
lgg
enhanc
adhes
e
coli
serotyp
human
intestin
mucu
lee
et
al
l
rhamnosu
strain
similar
effect
increment
adhes
salmonella
typhimurium
tuomola
et
al
also
enterococcu
faecium
strain
veterinari
use
improv
adhes
campylobact
jejuni
rinkinen
et
al
therefor
seem
specif
combin
probioticpathogen
may
repres
potenti
risk
increas
interact
pathogen
mucosa
situat
observ
l
casei
e
coli
nissl
assay
inhibit
pparticl
bind
cell
rubiodelcampo
et
al
exclus
displac
experi
show
bacteria
enhanc
retent
subvir
particl
cell
surfac
suggest
possibl
specif
case
virus
take
advantag
intestin
microbiota
particular
bacteria
reach
target
cell
accord
result
infect
human
nov
b
cell
situat
probabl
also
encount
vivo
whether
specif
probiot
block
viral
attach
convers
contribut
cellular
surfac
bind
need
explor
rv
nov
use
oligosaccharid
glycoconjug
cellular
surfac
receptor
attach
entri
rv
recogn
sialic
acid
nacetylneuramin
acid
residu
first
step
cellular
entri
alreadi
mention
nov
display
bind
specif
toward
carbohydr
carbohydr
form
part
hbga
express
mucos
surfac
mani
bacteri
speci
also
bind
glycosyl
surfac
protein
via
adhesin
take
advantag
glycoconjug
present
mucosa
carbon
sourc
suscept
nov
infect
relat
hbga
type
individu
secretor
statu
determin
presenc
h
antigen
secret
epithelia
link
gene
special
relev
shown
antibodi
preval
titer
nov
depend
secretor
statu
rather
blood
group
larsson
et
al
thu
nov
infect
depend
gut
microbiota
secretor
statu
could
possibl
gut
microbiota
also
depend
secretor
statu
recent
studi
shown
exactli
wacklin
et
al
wacklin
et
al
human
gut
microbiota
hgm
composit
vari
depend
genotyp
individu
defect
less
suscept
nov
infect
time
less
divers
intestin
microbiota
present
mark
diminish
number
bifidobacterium
bifidum
bifidobacterium
adolescenti
bifidobacterium
catenulatumpseudocatenulatum
wacklin
et
al
establish
link
secretor
statu
nov
suscept
microbiota
interestingli
specif
member
microbiota
bacteroid
thetaiotaomicron
modul
fucosyl
state
surfac
glycan
enterocyt
regul
host
fucosyl
pathway
bri
et
al
speci
strain
l
casei
secret
solubl
factor
cultur
supernat
increas
surfac
galactos
content
enterocyt
cell
limit
rv
infect
varyukhina
et
al
thu
complex
gut
ecosystem
viral
infect
studi
consid
mani
aspect
includ
host
genet
background
glycobiolog
gut
microbiota
recent
review
scientif
data
describ
evid
protect
confer
probiot
intestin
viral
infect
vitro
laboratori
anim
studi
clinic
trial
rodriguezdiaz
monedero
present
section
intend
updat
data
track
new
evid
publish
sinc
due
import
exist
proper
vitro
vivo
model
evid
effect
probiot
obtain
rv
viral
model
way
rv
select
pathogen
clinic
trial
efficaci
probiot
viral
pathogen
investig
due
great
preval
virus
infantil
popul
even
introduct
rv
vaccin
exist
diagnost
tool
detect
fortun
new
research
probiot
nov
virus
respons
great
major
gastroenter
publish
use
nov
surrog
vitro
least
one
clinic
trial
human
new
data
also
present
respect
virus
intestin
tract
transmiss
gastroenter
coronaviru
tgc
probiot
also
prove
effect
virus
includ
respiratori
virus
al
kassaa
et
al
discuss
chapter
vitro
model
special
interest
studi
abil
probiot
block
viral
infect
also
unravel
mechan
inhibit
cellular
level
well
establish
rv
well
nov
util
oligosaccharid
surfac
cell
first
step
viral
infect
receptor
coreceptor
varyukhina
collabor
shown
glycanmodifi
bacteria
probiot
bacteria
l
casei
commens
bacteria
bacteroid
thetaiotaomicron
abl
inhibit
rv
infect
mucu
secretor
human
cell
line
modif
glycan
surfac
cell
modif
made
secret
solubl
factor
bacteria
prove
effect
util
galactosyltransferas
bovin
milk
varyukhina
et
al
novel
mechan
antirv
activ
recent
describ
probiot
yeast
boulardii
author
work
investig
role
oxid
stress
reactiv
oxygen
speci
oxid
reduc
glutathion
chlorid
secret
induc
rv
toxin
human
epitheli
cell
antioxid
nacetylcystein
supernat
boulardii
cultur
abl
prevent
rv
chlorid
secret
via
reduct
oxid
stress
propos
mechan
action
product
unidentifi
solubl
metabolit
boulardii
prevent
oxid
stress
buccigrossi
et
al
vitro
studi
also
util
recent
evalu
novel
probiot
strain
effort
interest
character
potenti
probiot
new
bacteri
isol
clue
report
probiot
exert
function
new
probiot
bacterium
bifidobacterium
longum
subsp
infanti
show
antirv
activ
cell
munoz
et
al
similarli
three
new
bacteria
isol
fece
breastf
infant
lactobacillu
paracasei
cncm
b
breve
cncm
l
rhamnosu
cncm
analyz
antirv
activ
cell
supernat
l
rhamnosu
cncm
l
paracasei
cncm
prove
straindepend
antivir
activ
b
breve
cncm
antirv
activ
munozquezada
et
al
despit
great
import
health
human
nov
difficult
cultiv
vitro
cell
cultur
system
impair
studi
includ
investig
potenti
probiot
recent
differ
nov
surrog
util
studi
antinv
activ
differ
bacteri
strain
lee
collabor
report
inactiv
felin
caliciviru
murin
nov
ferment
dongchimi
korean
veget
ferment
product
case
evid
mode
action
bacteria
respons
effect
obtain
repres
first
report
shed
light
nov
inactiv
ferment
product
lee
et
al
recent
felin
caliciviru
also
util
human
nov
surrog
studi
antivir
activ
probiot
strain
lactococcu
lacti
subsp
lacti
author
show
preincub
viru
bacteri
cell
well
filtrat
cultur
media
reduc
viral
infect
aboubakr
et
al
perhap
util
human
nov
surrog
structur
function
antigen
studi
nov
vlp
nov
pparticl
last
surrog
util
assay
abil
sever
probiot
nonprobiot
bacteria
intestin
food
origin
bind
human
nov
studi
whether
bind
produc
impair
novhost
interact
interestingli
bacteria
l
casei
e
coli
nissl
nov
pparticl
genotyp
coadminist
cell
reduct
nov
pparticl
bind
cell
found
either
nov
pparticl
probiot
bacteria
preincub
cell
increas
nov
particl
bind
observ
rubiodelcampo
et
al
alreadi
discuss
surpris
enhanc
effect
probiot
nov
attach
recent
corrobor
establish
human
nov
cell
cultur
system
particip
gut
microbiota
tgc
viru
great
import
pig
farm
produc
acut
diarrhea
pig
caus
high
mortal
newborn
piglet
put
probiot
bacteria
lactobacillu
spp
probio
probio
isol
porcin
gastrointestin
tract
shown
antitgc
activ
vitro
filtrat
supernat
isol
abl
reduc
tgc
infect
st
cell
kumar
et
al
similarli
probiot
e
faecium
ncimb
strain
abl
inhibit
tgc
viru
infect
increas
st
cell
viabil
case
four
protocol
studi
includ
pretreat
cell
competit
postinfect
treatment
cellfre
preincub
four
case
antivir
doserespons
effect
observ
chai
et
al
similar
vitro
studi
anim
model
util
studi
efficaci
probiot
mostli
obtain
mechanist
inform
confer
protect
case
new
data
obtain
rv
three
differ
anim
model
includ
rat
mice
pig
top
studi
singl
probiot
strain
pathogen
rv
effect
hgm
transplant
use
vaccin
strain
rv
also
address
recent
result
point
modul
host
immun
system
main
mechan
probiot
help
organ
fight
rv
diarrhea
ventola
collabor
util
newborn
rat
model
studi
effect
live
dead
lgg
simian
rv
strain
reduct
diarrhea
observ
author
found
live
dead
probiot
possess
benefici
effect
rat
pup
term
prevent
reduct
bodi
weight
loss
prevent
colon
swell
compar
infect
control
group
ventola
et
al
adult
mice
model
util
confirm
antirv
properti
probiot
bacteri
strain
b
longum
subsp
infanti
author
found
delay
rotaviru
shed
h
postinfect
lower
antigen
concentr
day
infect
thu
confirm
previou
vitro
result
munoz
et
al
interest
result
obtain
newborn
mice
model
reduct
diarrhea
result
better
understand
antirv
effect
probiot
probiot
strain
l
gasseri
heat
inactiv
util
feed
fertil
adult
femal
mice
dam
subsequ
oral
immun
rv
strain
birth
pup
immun
femal
challeng
rv
diarrhea
iga
record
studi
show
reduct
diarrhea
pup
group
mice
fed
associ
higher
product
iga
immun
dam
also
receiv
probiot
kadooka
et
al
two
differ
strain
l
reuteri
dsm
atcc
pta
also
util
neonat
mice
model
newborn
mice
infect
homolog
rv
murin
strain
ec
subsequ
treat
probiot
strain
abl
reduc
durat
diarrhea
author
could
explain
benefici
effect
probiot
variou
mechan
includ
suppress
proinflammatori
molecul
macrophag
inflammatori
also
reduct
observ
togeth
increas
antirv
specif
antibodi
administr
probiot
also
improv
intestin
histopatholog
enhanc
intestin
microbiom
rich
phylogenet
divers
preidi
et
al
differ
dose
time
administr
lgg
assay
also
newborn
mice
evalu
differ
intervent
probiot
bacteria
author
found
effici
intervent
pretreat
pup
higher
dose
bacteria
shorten
diarrhea
reduct
epithelium
vacuol
jejunum
could
explain
increas
antirv
iga
gnotobiot
gn
piglet
model
util
sever
studi
recent
year
studi
modul
immun
respons
probiot
help
fight
rotaviru
infect
sens
azevedo
cowork
show
combin
l
acidophilu
l
reuteri
modul
cytokin
respons
gn
pig
infect
human
rv
suggest
regulatori
role
lactic
acid
bacteria
maintain
gut
homeostasi
azevedo
et
al
gn
piglet
model
also
util
studi
effect
differ
dosag
proinflammatori
l
acidophilu
ncfm
use
adjuv
human
rv
vaccin
interestingli
low
dose
ncfm
increas
tcell
respons
downregul
product
compar
high
dose
result
highli
relev
probiot
bacteria
differ
dosag
opposit
effect
either
promot
suppress
produc
cell
treg
cell
immun
respons
wen
et
al
combin
two
probiot
lgg
b
lacti
util
combin
milk
colostrum
colmilk
immun
respons
human
rv
attenu
vaccin
atthrv
studi
complex
studi
design
make
difficult
draw
conclus
word
author
colmilk
compon
solubl
mediat
affect
initi
probiot
colon
togeth
modul
neonat
antibodi
respons
oral
atthrv
vaccin
complex
way
subsequ
studi
author
evalu
probiot
gn
piglet
model
respons
atthrv
virul
human
rv
strain
similar
observ
differ
dose
probiot
modul
immunolog
respons
mediat
lggand
gn
piglet
virul
rv
differ
respons
vaccin
strain
chattha
et
al
combin
lgg
also
modul
innat
immun
respons
rv
gn
piglet
model
author
show
combin
vaccin
colon
lgg
complet
abolish
diarrhea
virul
rv
challeng
immunomatur
reflect
increas
frequenc
mhcii
express
mononuclear
cell
mnc
convent
dendrit
cell
intestin
tissu
blood
postchalleng
gn
pig
also
util
studi
mechan
lgg
protect
confer
rv
author
show
lgg
abl
protect
ileal
epithelium
virul
human
rotaviru
injuri
oral
treatment
strain
increas
integr
epithelium
compensatori
express
tight
junction
protein
occludin
leak
protein
lgg
also
increas
mucin
product
maintain
serum
level
proinflammatori
cytokin
lgg
also
shown
protect
rv
challeng
gn
piglet
model
novel
mechan
reduc
autophagi
induc
rv
induct
treatment
lgg
reduc
autophagi
marker
autophagi
regul
mtor
prevent
virusinduc
tissu
damag
wu
et
al
interest
result
obtain
model
transplant
hgm
gn
pig
carri
argu
lack
microbiota
gn
piglet
model
may
interfer
obtain
result
especi
probiot
strain
use
human
obvious
deplet
microbiota
two
recent
investig
address
issu
use
transplant
model
hgm
gn
piglet
wellcharacter
lgg
strain
util
gn
pig
hgm
transplant
gn
pig
expect
hgm
group
differ
gn
pig
respons
lgg
treatment
hgm
group
enhanc
cellular
immun
lgg
treatment
affect
antibodi
respons
comparison
gn
piglet
also
respond
increas
antibodi
respons
rv
author
argu
higher
dose
lgg
might
need
overtak
influenc
transplant
microbiota
achiev
immunostimulatori
effect
hgm
pig
effort
valid
transplant
hgm
gn
piglet
model
research
group
show
lgg
virul
human
rv
modul
transplant
hgm
similarli
happen
human
natur
gut
microbiota
suggest
hgm
pig
model
valuabl
test
respons
microbiota
probiot
intervent
vitro
studi
anim
model
valuabl
tool
character
new
put
probiot
elucid
underli
mechan
action
none
substitut
clinic
trial
studi
safeti
efficaci
probiot
intervent
human
sinc
last
revis
varieti
clinic
trial
publish
differ
probiot
result
variabl
administr
protocol
studi
design
make
difficult
obtain
gener
conclus
publish
intervent
detect
safeti
issu
relat
administ
probiot
shown
ineffici
treatment
rvinduc
diarrhea
also
first
time
use
probiot
address
novinduc
diarrhea
human
opencas
control
studi
conduct
assay
efficaci
l
casei
shirota
nov
elderli
studi
enrol
adult
averag
age
year
author
found
daili
consumpt
milk
ferment
probiot
prevent
diarrhea
produc
nov
reduct
mean
durat
fever
observ
nagata
et
al
sever
clinic
trial
perform
last
year
studi
effect
sever
probiot
rv
infant
popul
boulardii
shown
effici
rv
diarrhea
infant
doubleblind
placebocontrol
studi
brazil
studi
includ
infant
confirm
posit
rotaviru
commerci
elisa
test
infant
receiv
probiot
yeast
mgday
day
onset
diarrhea
reduc
diarrhea
durat
thu
prove
effici
correa
et
al
anoth
random
doubleblind
placebocontrol
clinic
trial
perform
studi
effect
bacillu
coagulan
rv
diarrhea
children
kolkata
india
case
author
find
benefici
effect
confer
probiot
strain
studi
popul
dutta
et
al
also
random
doubleblind
placebocontrol
clinic
trial
involv
infant
month
age
use
l
reuteri
dsm
probiot
strain
show
benefici
effect
rvproduc
diarrhea
wank
szajewska
efficaci
rv
b
lacti
boulardii
assay
prospect
random
clinic
trial
children
treatment
result
shorten
diarrhea
durat
compar
nonprobiot
group
erdogan
et
al
novel
probiot
combin
call
biothre
compos
three
differ
bacteria
strain
enterococcu
faecali
clostridium
butyricum
bacillu
mesentericu
test
rvand
salmonellaproduc
diarrhea
singl
center
openlabel
control
clinic
trial
trial
involv
patient
month
year
age
confirm
rv
posit
result
show
reduct
diarrhea
durat
effect
diarrhea
sever
lgg
one
bettercharacter
probiot
vitro
vivo
clinic
trial
aggarw
collabor
show
efficaci
lgg
reduct
durat
diarrhea
opencas
control
studi
india
enrol
children
rv
nonrv
diarrhea
aggarw
et
al
interestingli
sindhu
collabor
perform
random
doubleblind
placebocontrol
trial
children
n
infect
rv
cryptosporidium
protozoan
parasit
children
infect
rv
also
receiv
lgg
exhibit
fewer
repeat
diarrheal
episod
impair
intestin
function
intervent
group
also
signific
increas
igg
level
postintervent
sindhu
et
al
one
studi
human
provid
mechanist
explan
probiot
mechan
action
viral
diarrhea
unfortun
unif
studi
design
differ
test
probiot
exist
date
furthermor
studi
conduct
singl
center
rel
small
number
patient
european
societi
pediatr
gastroenterolog
hepatolog
nutrit
european
societi
pediatr
infecti
diseas
recent
publish
evidencebas
guidelin
manag
acut
gastroenter
children
europ
guid
two
probiot
strain
lgg
boulardii
strongli
recommend
alway
combin
oral
rehydr
interestingli
recommend
accompani
moder
low
qualiti
evid
reduct
durat
intens
symptom
indic
scientif
evid
need
warranti
benefici
activ
probiot
fight
viral
diarrhea
human
immunomodul
emerg
plausibl
mechan
probiot
exert
antivir
effect
gastrointestin
tract
scientif
data
mechan
still
scarc
clinic
trial
support
use
specif
strain
allevi
diarrhea
symptom
reduc
durat
mostli
children
howev
standard
treatment
protocol
strain
dose
frequenc
still
need
dual
role
microbiota
suscept
viral
infect
viral
pathogen
benefit
microbiota
infect
inhibit
may
constitut
basi
new
antivir
therapi
knowledg
virushostmicrobiota
interact
extend
provid
new
inform
specif
bacteria
play
role
interact
exploit
virus
known
probiot
modul
composit
microbiota
consequ
envisag
level
differ
bacteria
could
manipul
interact
mechan
disturb
use
probiot
dietari
intervent
